These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26394646)

  • 1. Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease.
    Almquist T; Mobarrez F; Jacobson SH; Wallén H; Hjemdahl P
    Nephrol Dial Transplant; 2016 Jun; 31(6):944-52. PubMed ID: 26394646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.
    Almquist T; Jacobson SH; Mobarrez F; Näsman P; Hjemdahl P
    Eur J Clin Invest; 2014; 44(3):276-84. PubMed ID: 24720535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial.
    Almquist T; Jacobson SH; Lins PE; Farndale RW; Hjemdahl P
    Nephrol Dial Transplant; 2012 Sep; 27(9):3540-6. PubMed ID: 22700717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased concentrations of platelet- and endothelial-derived microparticles in patients with myocardial infarction and reduced renal function- a descriptive study.
    Mörtberg J; Lundwall K; Mobarrez F; Wallén H; Jacobson SH; Spaak J
    BMC Nephrol; 2019 Mar; 20(1):71. PubMed ID: 30823870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meal intake increases circulating procoagulant microparticles in patients with type 1 and type 2 diabetes mellitus.
    Spectre G; Mobarrez F; Stålesen R; Östenson CG; Varon D; Wallen H; Hjemdahl P
    Platelets; 2019; 30(3):348-355. PubMed ID: 29547014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.
    Stanifer JW; Charytan DM; White J; Lokhnygina Y; Cannon CP; Roe MT; Blazing MA
    J Am Soc Nephrol; 2017 Oct; 28(10):3034-3043. PubMed ID: 28507057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microparticles as new markers of cardiovascular risk in diabetes and beyond.
    Santilli F; Marchisio M; Lanuti P; Boccatonda A; Miscia S; Davì G
    Thromb Haemost; 2016 Aug; 116(2):220-34. PubMed ID: 27173919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microparticles during long-term follow-up after acute myocardial infarction. Association to atherosclerotic burden and risk of cardiovascular events.
    Christersson C; Thulin Å; Siegbahn A
    Thromb Haemost; 2017 Jul; 117(8):1571-1581. PubMed ID: 28424820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased blood cell phosphatidylserine exposure and circulating microparticles contribute to procoagulant activity after carotid artery stenting.
    Zhao L; Wu X; Si Y; Yao Z; Dong Z; Novakovic VA; Guo L; Tong D; Chen H; Bi Y; Kou J; Shi H; Tian Y; Hu S; Zhou J; Shi J
    J Neurosurg; 2017 Nov; 127(5):1041-1054. PubMed ID: 28009236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
    Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
    Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation.
    Lau YC; Xiong Q; Blann AD; Lip GY
    J Thromb Thrombolysis; 2017 Jan; 43(1):18-23. PubMed ID: 27671694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?
    Green D; Panayotova R; Ritchie JP; O'Riordan E; McDonald J
    J Ren Care; 2012 Sep; 38(3):138-46. PubMed ID: 22613701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
    Zinellu A; Sotgia S; Mangoni AA; Sotgiu E; Ena S; Satta AE; Carru C
    J Pharm Biomed Anal; 2016 Sep; 129():383-388. PubMed ID: 27454090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Diabetes on Circulating Apoptotic Microparticles in Patients with Chronic Hepatitis C.
    Zuwala-Jagiello J; Pazgan-Simon M; Murawska-Cialowicz E; Simon K
    In Vivo; 2017; 31(5):1027-1034. PubMed ID: 28882977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
    Mobarrez F; He S; Bröijersen A; Wiklund B; Antovic A; Antovic J; Egberg N; Jörneskog G; Wallén H
    Thromb Haemost; 2011 Aug; 106(2):344-52. PubMed ID: 21614411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients.
    Lins LC; França CN; Fonseca FA; Barbosa SP; Matos LN; Aguirre AC; Bianco HT; do Amaral JB; Izar MC
    Cell Biochem Biophys; 2014 Sep; 70(1):687-96. PubMed ID: 24777811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of circulatory platelet microparticles and endothelial microparticles in patients with chronic kidney disease.
    Lu GY; Xu RJ; Zhang SH; Qiao Q; Shen L; Li M; Xu DY; Wang ZY
    Int J Clin Exp Med; 2015; 8(9):16704-8. PubMed ID: 26629207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of microparticles in the injured brain of patients with severe isolated traumatic brain injury.
    Nekludov M; Mobarrez F; Gryth D; Bellander BM; Wallen H
    J Neurotrauma; 2014 Dec; 31(23):1927-33. PubMed ID: 24956150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.